A new research paper was published in Oncotarget entitled, "Novel therapeutic bispecific antibodies for B-cell lymphoma targeting IgM and other antigens on the B-cell surface."
Apr 16, 2024
0
0
Patients with some types of lymphoma that become resistant to standard treatments may benefit from a therapy that University of Wisconsin–Madison researchers are evaluating after they discovered a key process that fuels ...
Mar 16, 2024
0
48
Combination treatments with two or more blood pressure drugs can significantly reduce blood pressure in patients taking ibrutinib, according to a new study published in Blood Advances.
Feb 5, 2024
0
0
Proteasomes are protein-degrading complexes that are important for cancer cell survival. Proteasome inhibitors are commonly used to treat diseases such as multiple myeloma and mantle cell lymphoma. Proteasomes have three ...
Dec 14, 2023
0
15
Survivors of common lymphoid neoplasms (LNs) have increased risks for therapy-related myelodysplastic syndrome/acute myeloid leukemia (tMDS/AML), although risks have been lower in more recent years, according to a study published ...
Aug 17, 2023
0
29
A new research paper titled "Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma" has been published in Oncotarget.
Dec 13, 2022
0
3
A form of blood cancer known as mantle cell lymphoma is critically dependent on a protein that coordinates gene expression, such that blocking its activity with an experimental drug dramatically slows the growth of this lymphoma ...
Nov 22, 2022
0
26
A new molecular imaging radiotracer can precisely diagnose a variety of cancers, providing a roadmap to identify patients who may benefit from targeted radionuclide therapies. In the largest medical study of its kind, researchers ...
Nov 17, 2022
0
49
There is considerable variation in the management of mantle cell lymphoma across different clinical settings, and some strategies do not always conform with what might be expected, according to an analysis by investigators ...
Jun 28, 2022
0
5
Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle cell lymphoma (MCL) ...
Jun 3, 2022
0
35
